-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical News, February 26.
In the current pharmaceutical industry, the self-research and innovative development model represented by Hengrui and the M&A expansion model represented by Fosun are the two most typical expansion models of pharmaceutical companies.
In the current pharmaceutical industry, the self-research and innovative development model represented by Hengrui and the M&A expansion model represented by Fosun are the two most typical expansion models of pharmaceutical companies.
Driven by capital, local veteran pharmaceutical giants, who have built their pharmaceutical kingdom through investment and mergers and achieved rapid expansion, are showing their magical powers in order to realize the two-wheel drive of endogenous and extension.
At the current stage, the R&D model of independent R&D + external M&A + license introduction is becoming a way for pharmaceutical giants to endogenously extend and integrate vertically.
At the current stage, the R&D model of independent R&D + external M&A + license introduction is becoming a way for pharmaceutical giants to endogenously extend and integrate vertically.
Under the capital layout, the pharmaceutical giants quickly enriched the product pipelines in core areas and completed the pipeline layout of innovative products in the core areas, providing new momentum for medium and long-term growth.
01 founder Wang to return A copy of the
"Shocked! Zhongsheng is going back to the Science and Technology Innovation Board.
"
"
On the evening of February 3, China Biopharmaceuticals announced that it plans to be listed on the Science and Technology Innovation Board.
According to the announcement, all the stocks to be issued by China Biopharmaceutical on the Sci-tech Innovation Board are new shares, and the funds raised are intended to be used for the development of main business, mergers and acquisitions and integration in the industry, and general working capital.
According to the announcement, all the stocks to be issued by China Biopharmaceutical on the Sci-tech Innovation Board are new shares, and the funds raised are intended to be used for the development of main business, mergers and acquisitions and integration in the industry, and general working capital.
China Biopharmaceuticals' pace of returning to A is approaching.
On the evening of February 23, the official website of the Beijing Securities Regulatory Bureau disclosed the basic information of CICC and CITIC Securities on the IPO guidance of China Biopharmaceutical Co.
, Ltd.
on the Science and Technology Innovation Board.
China Biopharmaceutical Co.
, Ltd.
has signed a counseling agreement with CICC and CITIC Securities on February 8, 2021.
, Ltd.
on the Science and Technology Innovation Board.
China Biopharmaceutical Co.
, Ltd.
has signed a counseling agreement with CICC and CITIC Securities on February 8, 2021.
Sino Biopharmaceuticals was listed on the main board of the Hong Kong Stock Exchange in September 2000.
So far, its market value has exceeded 160 billion Hong Kong dollars.
It is reported that China Biopharma's business covers the entire industry chain of various pharmaceutical research and development platforms, intelligent production and strong sales systems.
Its products include a variety of biological drugs and chemical drugs, and are in an advantageous position in many potential therapeutic fields such as liver disease, tumor, orthopedics, anti-infection and respiratory diseases.
So far, its market value has exceeded 160 billion Hong Kong dollars.
It is reported that China Biopharma's business covers the entire industry chain of various pharmaceutical research and development platforms, intelligent production and strong sales systems.
Its products include a variety of biological drugs and chemical drugs, and are in an advantageous position in many potential therapeutic fields such as liver disease, tumor, orthopedics, anti-infection and respiratory diseases.
It is true that the pharmaceutical empire of a giant with a market value of hundreds of billions was not built in a day.
The rich capital operation experience and strong project cooperation capabilities of the pharmaceutical industry have enabled China's biopharmaceuticals to continue to expand their pharmaceutical footprint.
Since the establishment of Chia Tai Tianqing as a joint venture with Jiangsu Tianqing in 1997, Sino Biopharmaceuticals has successively controlled Chia Tai Tianqing, Nanjing Chia Tai Tianqing, Beijing Tide, Chia Tai Fenghai, Chia Tai Qingjiang, and Chia Tai Pharmaceutical Qingdao through new construction or investment acquisitions.
And other major subsidiaries.
Since the establishment of Chia Tai Tianqing as a joint venture with Jiangsu Tianqing in 1997, Sino Biopharmaceuticals has successively controlled Chia Tai Tianqing, Nanjing Chia Tai Tianqing, Beijing Tide, Chia Tai Fenghai, Chia Tai Qingjiang, and Chia Tai Pharmaceutical Qingdao through new construction or investment acquisitions.
And other major subsidiaries.
China Biopharmaceuticals, which started with generic drugs, are being impacted by volume pharmnet.
com.
cn/news/yyzb/" target="_blank">purchases .
com.
cn/news/yyzb/" target="_blank">purchases .
The third quarter report of 2020 shows that China's biopharmaceutical revenue was 5.
478 billion yuan, a year-on-year decrease of 19.
36% and a month-on-month decrease of 14.
75%.
In the same period last year, China's biopharmaceutical revenue increased by 13.
13% year-on-year and 7.
5% month-on-month.
478 billion yuan, a year-on-year decrease of 19.
36% and a month-on-month decrease of 14.
75%.
In the same period last year, China's biopharmaceutical revenue increased by 13.
13% year-on-year and 7.
5% month-on-month.
Liver disease drugs are the leading product and largest source of income of China Biopharmaceuticals.
With the advancement of three batches of four rounds of national centralized procurement, involving many major products in the field of liver disease under China Biopharmaceuticals, the impact of centralized procurement is gradually showing, and its liver disease revenue will be significantly reduced in 2020.
The third quarterly report for 2020 shows that China's biopharmaceutical liver disease product revenue was 803 million yuan, a year-on-year decline of 52.
03%.
With the advancement of three batches of four rounds of national centralized procurement, involving many major products in the field of liver disease under China Biopharmaceuticals, the impact of centralized procurement is gradually showing, and its liver disease revenue will be significantly reduced in 2020.
The third quarterly report for 2020 shows that China's biopharmaceutical liver disease product revenue was 803 million yuan, a year-on-year decline of 52.
03%.
The income of liver disease drugs is sluggish, and anti-tumor drugs have failed to carry the banner of performance growth.
In the third quarter of 2020, anti-tumor drug revenue was 1.
637 billion yuan, an increase of only 8.
42% year-on-year.
Although the revenue growth rate of orthopedic drugs, anti-infective drugs and respiratory system drugs was relatively high, 13.
58%, 14.
61%, and 35.
64%, respectively, due to the small scale of products, the performance decline of China's biopharmaceuticals could not be saved.
In the third quarter of 2020, anti-tumor drug revenue was 1.
637 billion yuan, an increase of only 8.
42% year-on-year.
Although the revenue growth rate of orthopedic drugs, anti-infective drugs and respiratory system drugs was relatively high, 13.
58%, 14.
61%, and 35.
64%, respectively, due to the small scale of products, the performance decline of China's biopharmaceuticals could not be saved.
However, as the “king of the first imitation” in China, China Biopharmaceuticals, while carrying out the strategic transformation of combining innovation and imitation, is also constantly strengthening its traditional advantages, attacking the first imitation drugs and difficult imitation drugs, and only making the first three imitations.
It will help reduce the risk of centralized procurement of its generic drugs in the future.
It will help reduce the risk of centralized procurement of its generic drugs in the future.
When traditional areas of advantage are impacted, investment and license introduction are becoming its new growth point and innovative transformation means.
Although it is not too early to start on the road of innovation and transformation, with its strong extensional cooperation capabilities, China Biopharmaceuticals has a trend of overtaking in corners.
In terms of licensing, China Biopharmaceuticals signed agreements with companies such as Abpro, Ambrx, and Octapharma AG to introduce products such as double antibodies, innovative drugs for liver disease, and human albumin.
Not only is it licensed to introduce, China Biopharmaceuticals has also frequently invested in local emerging biotech companies in recent years.
Appeared in the prospectus of Yasheng Pharmaceutical and Rongchang Biological as a cornerstone investor ; led the US$150 million round D financing of Kangfang Biological; invested more than US$500 million in Kexing Zhongwei to promote the new crown vaccine project.
.
.
Appeared in the prospectus of Yasheng Pharmaceutical and Rongchang Biological as a cornerstone investor ; led the US$150 million round D financing of Kangfang Biological; invested more than US$500 million in Kexing Zhongwei to promote the new crown vaccine project.
.
.
China Biopharmaceuticals is controlled by Xie Bing, executive vice president of Thailand's CP Group and his family.
Xie Bing single-handedly founded China Biopharmaceuticals and has been in charge for many years.
Since 2015, Xie Bing’s daughter Xie Qirun and son Xie Chengrun have gradually stepped onto the front desk, and China Biopharmaceuticals have gradually Enter a new era.
Xie Bing single-handedly founded China Biopharmaceuticals and has been in charge for many years.
Since 2015, Xie Bing’s daughter Xie Qirun and son Xie Chengrun have gradually stepped onto the front desk, and China Biopharmaceuticals have gradually Enter a new era.
In October 2019, China Biopharmaceuticals announced that the executive director and major shareholders Xie Bing and Zheng Xiangling had transferred 450 million and 2.
25 billion company shares, respectively, to their son Xie Chengrun as gifts.
After the completion of the transfer, Xie Chengrun held a total of 2.
7 billion shares of the company, and its shareholding ratio reached 21.
45%.
25 billion company shares, respectively, to their son Xie Chengrun as gifts.
After the completion of the transfer, Xie Chengrun held a total of 2.
7 billion shares of the company, and its shareholding ratio reached 21.
45%.
In addition to Xie Chengrun, Xie Bing's daughter Xie Qirun is also worth mentioning.
In June 2015, Xie Bing ceded the chairman of the board to his 23-year-old daughter Xie Qirun.
And half a year after taking over China Biopharmaceutical Company, Xie Qirun handed over an answer sheet with an annual revenue of 14.
5 billion yuan and a profit of 1.
778 billion yuan, successfully breaking all previous records of China Biopharmaceutical Company and setting a new high profit.
In June 2015, Xie Bing ceded the chairman of the board to his 23-year-old daughter Xie Qirun.
And half a year after taking over China Biopharmaceutical Company, Xie Qirun handed over an answer sheet with an annual revenue of 14.
5 billion yuan and a profit of 1.
778 billion yuan, successfully breaking all previous records of China Biopharmaceutical Company and setting a new high profit.
In August 2020, Xie Bing resigned as CEO of China Biopharmaceuticals, and instead hired Li Yi, a former senior executive of JP Morgan Chase, with an annual salary of tens of millions.
Now it seems that Li Yi’s participation may bring more changes to this established pharmaceutical company from the capital market.
Now it seems that Li Yi’s participation may bring more changes to this established pharmaceutical company from the capital market.
02 PE "Family History" in the pharmaceutical industry
Fosun Pharma and Broad Pharmaceutical, both of which are capital giants, are representatives of "buy, buy, buy".
Shanghai Fosun Industrial Co.
, Ltd.
(now Fosun Pharma), established in 1994, is the first and most important step for Fosun Group to enter the pharmaceutical industry.
In 1998, Fosun Pharma was successfully listed on the Shanghai Stock Exchange and listed on the A-share market, becoming the "first share" of a private company in Shanghai.
In October 2012, Fosun Pharma successfully completed the issuance and listing of H shares in Hong Kong, forming a capital market layout of A+H shares.
, Ltd.
(now Fosun Pharma), established in 1994, is the first and most important step for Fosun Group to enter the pharmaceutical industry.
In 1998, Fosun Pharma was successfully listed on the Shanghai Stock Exchange and listed on the A-share market, becoming the "first share" of a private company in Shanghai.
In October 2012, Fosun Pharma successfully completed the issuance and listing of H shares in Hong Kong, forming a capital market layout of A+H shares.
Relying on investment and mergers and acquisitions, Fosun Pharma quickly entered the fields of pharmaceuticals, medical devices , and medical services.
In 2009, Fosun Pharma and a team of overseas scientists formed a joint venture, Fosun Pharma, and began to get involved in the research and development of small molecule chemical drugs.
In 2010, Fuhong Henlius was established and began to deploy in the fields of tumors, autoimmune diseases, and ophthalmological diseases.
In the same year, Fosun Pharma and U.
S.
China Mutual Co.
, Ltd.
jointly established a joint venture company U.
S.
China Mutual Medical Co.
, Ltd.
in Hong Kong to enter the field of medical devices.
In the same year, Fosun Pharma and U.
S.
China Mutual Co.
, Ltd.
jointly established a joint venture company U.
S.
China Mutual Medical Co.
, Ltd.
in Hong Kong to enter the field of medical devices.
In 2013, Fosun Pharma established Fu Rui Medical and acquired Alma, a medical beauty equipment manufacturer.
While expanding the medical device product system, Fosun Pharma also achieved the first international industrial holding acquisition.
While expanding the medical device product system, Fosun Pharma also achieved the first international industrial holding acquisition.
In 2015, Fosun Pharma, Hopu Investment, Everbright and WuXi AppTec jointly acquired Ambrx, an innovative biopharmaceutical company in the United States.
Ambrx focuses on the discovery and development of innovative and cutting-edge protein drugs, and has developed pipelines including ADCs, bispecific and multispecific antibody drug complexes, and long-acting therapeutic proteins.
The acquisition of Ambrx is an expansion of Fosun Pharma in the field of innovative oncology drugs.
Ambrx focuses on the discovery and development of innovative and cutting-edge protein drugs, and has developed pipelines including ADCs, bispecific and multispecific antibody drug complexes, and long-acting therapeutic proteins.
The acquisition of Ambrx is an expansion of Fosun Pharma in the field of innovative oncology drugs.
In 2016, Fosun Pharma acquired Gland Pharma, an Indian pharmaceutical company, which provided strong support for it in the field of generic drugs.
In 2017, Fosun Pharma acquired the Swedish respiratory equipment company Breas and began to deploy the respiratory medicine business.
In the same year, Fosun Pharma acquired Tridem Pharma, the third largest pharmaceutical distribution company in the French-speaking area of West Africa, to expand the sales scale of its independently developed artesunate series products in the African market.
In the same year, Fosun Pharma and Kite Pharma (a subsidiary of Gilead) co-founded Fosun Kate and entered the field of T cell immunotherapy.
In the same year, Fosun Pharma acquired Tridem Pharma, the third largest pharmaceutical distribution company in the French-speaking area of West Africa, to expand the sales scale of its independently developed artesunate series products in the African market.
In the same year, Fosun Pharma and Kite Pharma (a subsidiary of Gilead) co-founded Fosun Kate and entered the field of T cell immunotherapy.
In 2018, Fosun Pharma invested in Butterfly Network to deploy super-generating imagers for smartphones to improve the accessibility of its medical service business.
In 2019, Fu Rui Medical acquired a 60% stake in Medicak Israel Ltd, an Israeli medical beauty distribution company.
In addition to acquiring the company, Fosun Pharma has successively acquired Zhejiang Dean Diagnostics, Yueyang Guangji Hospital , Anhui Jimin Cancer Hospital, United Family Hospital, Zhongwu Hospital, Nanyang Cancer Hospital and other hospitals.
To many cities and regions.
To many cities and regions.
In the past ten years, continuous investment and mergers and acquisitions have allowed Fosun Pharma to have more than 50 branches and holding companies, and this data has a tendency to expand.
Acquisition-style expansion has made investment income gradually become an important source of profit for Fosun Pharma, and Fosun Pharma is therefore known as the "PE" of the pharmaceutical industry.
Acquisition-style expansion has made investment income gradually become an important source of profit for Fosun Pharma, and Fosun Pharma is therefore known as the "PE" of the pharmaceutical industry.
The layout of Fosun Pharma's entire industrial chain is not only reflected in the acquisition of the company, but also in the introduction and research and development of blockbuster drugs.
In March 2018, Fosun Pharma introduced a new generation of TPO-RA drug avatropopag (trade name: Su Kexin), which is used for the treatment of thrombocytopenia and was approved for marketing in 2020.
In 2019, Fuhong Henlius' rituximab (trade name: Hanlikang) was approved for marketing, becoming the first domestic biosimilar drug.
Fosun Kate’s Car-T treatment is also about to be commercialized in China.
In 2020, BioNtech's new crown vaccine will be the first to "hit the line" and become the world's first new crown vaccine on the market.
Fosun Pharma's earlier introduction of BioNtech's new crown vaccine also fully demonstrated its unique vision for selection.
In 2019, Fuhong Henlius' rituximab (trade name: Hanlikang) was approved for marketing, becoming the first domestic biosimilar drug.
Fosun Kate’s Car-T treatment is also about to be commercialized in China.
In 2020, BioNtech's new crown vaccine will be the first to "hit the line" and become the world's first new crown vaccine on the market.
Fosun Pharma's earlier introduction of BioNtech's new crown vaccine also fully demonstrated its unique vision for selection.
According to data from the report of the third quarter of 2020 by Fosun Pharma, from January to September 2020, its research and development expenses reached 1.
87 billion yuan, which was an increase of 45.
5% compared with the 1.
29 billion yuan investment in research and development from January to September 2019.
Mainly to invest in research and development of biological drugs, small molecule innovative drugs and imported innovative drugs, and increase investment in innovation incubation platforms.
The opening of the independent research and development model gives Fosun Pharma another opportunity to show its vision.
87 billion yuan, which was an increase of 45.
5% compared with the 1.
29 billion yuan investment in research and development from January to September 2019.
Mainly to invest in research and development of biological drugs, small molecule innovative drugs and imported innovative drugs, and increase investment in innovation incubation platforms.
The opening of the independent research and development model gives Fosun Pharma another opportunity to show its vision.
As a company with a history of 88 years, Yuanda Pharmaceuticals has a stronger "buy, buy and buy" force than the previous two companies.
Broad Pharmaceutical was established in 1939 and joined China Broad Group in 2002.
In 2008, it was listed on the Hong Kong stock market.
In the same year, the acquisition of Wuhan Yuanda Hongyuan Co.
, Ltd.
was completed, and it was deployed in the field of amino acid production.
In 2008, it was listed on the Hong Kong stock market.
In the same year, the acquisition of Wuhan Yuanda Hongyuan Co.
, Ltd.
was completed, and it was deployed in the field of amino acid production.
In the following years, Yuanda Pharmaceutical started its acquisition and expansion road.
Acquired BROAD Tiantianming Pharmaceuticals and BROAD Fuchs Pharmaceuticals one after another to deploy in the field of ophthalmology and chemical medicine; acquired Wuhan Kono Biotechnology and entered the field of biological pesticides; acquired Hubei Shubang Pharmaceutical to enhance its competitiveness in the field of pharmaceutical production; Established a joint venture company with Huangshi Feiyun Pharmaceutical to expand its layout in traditional Chinese medicine and drug production; acquired Huajin Pharmaceutical to increase its competitiveness in the field of generic drugs; completed the acquisition of Jiuhe Pharmaceutical to increase its exposure to APIs Control; acquired Cardionovum of Germany and entered the field of cardiovascular interventional therapy; the acquisition of Xi'an Beilin Pharmaceutical Co.
, Ltd.
continued to supplement its layout in the field of ophthalmic drugs; joint venture into the Canadian Conavi company to enter the field of cardiovascular diagnostics; acquisition of Xudong Haipu Pharmaceutical It strengthened its control over the production of injection drugs; and CDH Investment spent nearly RMB 10 billion to acquire 100% of the shares of Sirtex, a listed Australian pharmaceutical company, and Broad Pharmaceuticals began to enter the field of interventional oncology.
, Ltd.
continued to supplement its layout in the field of ophthalmic drugs; joint venture into the Canadian Conavi company to enter the field of cardiovascular diagnostics; acquisition of Xudong Haipu Pharmaceutical It strengthened its control over the production of injection drugs; and CDH Investment spent nearly RMB 10 billion to acquire 100% of the shares of Sirtex, a listed Australian pharmaceutical company, and Broad Pharmaceuticals began to enter the field of interventional oncology.
Similarly, in addition to acquisitions, Yuanda Pharmaceutical also does not forget to invest in companies and "buy drugs.
"
"
In 2019, Broad Pharmaceutical obtained the Chinese market rights and interests of Indian pharmaceutical giant Glenmark's global new compound nasal spray product Ryaltris through investment.
In the same year, Broad Pharmaceutical signed an exclusive authorization and cooperative development agreement with Griffith University of Australia, and obtained the global development and commercialization rights of the world's first products for the treatment of parainfluenza and related technologies.
In addition, it has acquired the global development and commercialization rights of sepsis drugs from the Australian National Research University (ANU), and cooperates with them to develop sepsis drugs.
In the same year, Broad Pharmaceutical signed an exclusive authorization and cooperative development agreement with Griffith University of Australia, and obtained the global development and commercialization rights of the world's first products for the treatment of parainfluenza and related technologies.
In addition, it has acquired the global development and commercialization rights of sepsis drugs from the Australian National Research University (ANU), and cooperates with them to develop sepsis drugs.
In 2020, Grand Pharmaceuticals invested in Quanfu Biotechnology and Chongqing Antixin Biotechnology Co.
, Ltd.
, and included the world's first product BRM421 for the treatment of dry eye and the world's first new drug technology for the treatment of sepsis APAD.
In addition, it has also obtained the exclusive production and commercialization rights of CBT001, a global innovative ophthalmic product developed by Boyun Pharmaceutical, in the Chinese market.
, Ltd.
, and included the world's first product BRM421 for the treatment of dry eye and the world's first new drug technology for the treatment of sepsis APAD.
In addition, it has also obtained the exclusive production and commercialization rights of CBT001, a global innovative ophthalmic product developed by Boyun Pharmaceutical, in the Chinese market.
Of course, the acquisition and investment of foreign companies in Yuanda Pharmaceutical has not stopped.
In 2020, Broad Pharmaceutical acquired the controlling stake of OncoSec, a US-listed Nasdaq company, and acquired TAVO, the world's first tumor immunotherapy product.
By investing in Belgium's eTheRNA, Yuanda Pharmaceutical has introduced mRNA vaccine platform technology to expand its layout in the field of tumor immunotherapy and infectious disease treatment.
In 2020, Broad Pharmaceutical acquired the controlling stake of OncoSec, a US-listed Nasdaq company, and acquired TAVO, the world's first tumor immunotherapy product.
By investing in Belgium's eTheRNA, Yuanda Pharmaceutical has introduced mRNA vaccine platform technology to expand its layout in the field of tumor immunotherapy and infectious disease treatment.
However, with seemingly similar investment, mergers and acquisitions and licensing introduction models, China Biopharmaceuticals, Fosun Pharma, and Yuanda Pharmaceuticals have handed in different answers.
According to Flush data, as of press time, the market value of China Biopharmaceuticals was 160.
32 billion Hong Kong dollars (approximately 133.
35 billion yuan), Fosun Pharmaceuticals had a market value of 117.
38 billion yuan, and Broad Pharmaceuticals had a market value of 21.
9 billion Hong Kong dollars (approximately 18.
22 billion yuan).
According to Flush data, as of press time, the market value of China Biopharmaceuticals was 160.
32 billion Hong Kong dollars (approximately 133.
35 billion yuan), Fosun Pharmaceuticals had a market value of 117.
38 billion yuan, and Broad Pharmaceuticals had a market value of 21.
9 billion Hong Kong dollars (approximately 18.
22 billion yuan).
On the whole, behind the gap in market value are more comprehensive tests of market judgment, R&D and product selection capabilities.
Medical News, February 26.
In the current pharmaceutical industry, the self-research and innovative development model represented by Hengrui and the M&A expansion model represented by Fosun are the two most typical expansion models of pharmaceutical companies.
In the current pharmaceutical industry, the self-research and innovative development model represented by Hengrui and the M&A expansion model represented by Fosun are the two most typical expansion models of pharmaceutical companies.
Driven by capital, local veteran pharmaceutical giants, who have built their pharmaceutical kingdom through investment and mergers and achieved rapid expansion, are showing their magical powers in order to realize the two-wheel drive of endogenous and extension.
At the current stage, the R&D model of independent R&D + external M&A + license introduction is becoming a way for pharmaceutical giants to endogenously extend and integrate vertically.
At the current stage, the R&D model of independent R&D + external M&A + license introduction is becoming a way for pharmaceutical giants to endogenously extend and integrate vertically.
Under the capital layout, the pharmaceutical giants quickly enriched the product pipelines in core areas and completed the pipeline layout of innovative products in the core areas, providing new momentum for medium and long-term growth.
01 founder Wang to return A copy of the
"Shocked! Zhongsheng is going back to the Science and Technology Innovation Board.
"
"
On the evening of February 3, China Biopharmaceuticals announced that it plans to be listed on the Science and Technology Innovation Board.
According to the announcement, all the stocks to be issued by China Biopharmaceutical on the Sci-tech Innovation Board are new shares, and the funds raised are intended to be used for the development of main business, mergers and acquisitions and integration in the industry, and general working capital.
According to the announcement, all the stocks to be issued by China Biopharmaceutical on the Sci-tech Innovation Board are new shares, and the funds raised are intended to be used for the development of main business, mergers and acquisitions and integration in the industry, and general working capital.
China Biopharmaceuticals' pace of returning to A is approaching.
On the evening of February 23, the official website of the Beijing Securities Regulatory Bureau disclosed the basic information of CICC and CITIC Securities on the IPO guidance of China Biopharmaceutical Co.
, Ltd.
on the Science and Technology Innovation Board.
China Biopharmaceutical Co.
, Ltd.
has signed a counseling agreement with CICC and CITIC Securities on February 8, 2021.
, Ltd.
on the Science and Technology Innovation Board.
China Biopharmaceutical Co.
, Ltd.
has signed a counseling agreement with CICC and CITIC Securities on February 8, 2021.
Sino Biopharmaceuticals was listed on the main board of the Hong Kong Stock Exchange in September 2000.
So far, its market value has exceeded 160 billion Hong Kong dollars.
It is reported that China Biopharma's business covers the entire industry chain of various pharmaceutical research and development platforms, intelligent production and strong sales systems.
Its products include a variety of biological drugs and chemical drugs, and are in an advantageous position in many potential therapeutic fields such as liver disease, tumor, orthopedics, anti-infection and respiratory diseases.
So far, its market value has exceeded 160 billion Hong Kong dollars.
It is reported that China Biopharma's business covers the entire industry chain of various pharmaceutical research and development platforms, intelligent production and strong sales systems.
Its products include a variety of biological drugs and chemical drugs, and are in an advantageous position in many potential therapeutic fields such as liver disease, tumor, orthopedics, anti-infection and respiratory diseases.
It is true that the pharmaceutical empire of a giant with a market value of hundreds of billions was not built in a day.
The rich capital operation experience and strong project cooperation capabilities of the pharmaceutical industry have enabled China's biopharmaceuticals to continue to expand their pharmaceutical footprint.
Since the establishment of Chia Tai Tianqing as a joint venture with Jiangsu Tianqing in 1997, Sino Biopharmaceuticals has successively controlled Chia Tai Tianqing, Nanjing Chia Tai Tianqing, Beijing Tide, Chia Tai Fenghai, Chia Tai Qingjiang, and Chia Tai Pharmaceutical Qingdao through new construction or investment acquisitions.
And other major subsidiaries.
Since the establishment of Chia Tai Tianqing as a joint venture with Jiangsu Tianqing in 1997, Sino Biopharmaceuticals has successively controlled Chia Tai Tianqing, Nanjing Chia Tai Tianqing, Beijing Tide, Chia Tai Fenghai, Chia Tai Qingjiang, and Chia Tai Pharmaceutical Qingdao through new construction or investment acquisitions.
And other major subsidiaries.
China Biopharmaceuticals, which started with generic drugs, are being impacted by volume pharmnet.
com.
cn/news/yyzb/" target="_blank">purchases .
com.
cn/news/yyzb/" target="_blank">purchases .
The third quarter report of 2020 shows that China's biopharmaceutical revenue was 5.
478 billion yuan, a year-on-year decrease of 19.
36% and a month-on-month decrease of 14.
75%.
In the same period last year, China's biopharmaceutical revenue increased by 13.
13% year-on-year and 7.
5% month-on-month.
478 billion yuan, a year-on-year decrease of 19.
36% and a month-on-month decrease of 14.
75%.
In the same period last year, China's biopharmaceutical revenue increased by 13.
13% year-on-year and 7.
5% month-on-month.
Liver disease drugs are the leading product and largest source of income of China Biopharmaceuticals.
With the advancement of three batches of four rounds of national centralized procurement, involving many major products in the field of liver disease under China Biopharmaceuticals, the impact of centralized procurement is gradually showing, and its liver disease revenue will be significantly reduced in 2020.
The third quarterly report for 2020 shows that China's biopharmaceutical liver disease product revenue was 803 million yuan, a year-on-year decline of 52.
03%.
With the advancement of three batches of four rounds of national centralized procurement, involving many major products in the field of liver disease under China Biopharmaceuticals, the impact of centralized procurement is gradually showing, and its liver disease revenue will be significantly reduced in 2020.
The third quarterly report for 2020 shows that China's biopharmaceutical liver disease product revenue was 803 million yuan, a year-on-year decline of 52.
03%.
The income of liver disease drugs is sluggish, and anti-tumor drugs have failed to carry the banner of performance growth.
In the third quarter of 2020, anti-tumor drug revenue was 1.
637 billion yuan, an increase of only 8.
42% year-on-year.
Although the revenue growth rate of orthopedic drugs, anti-infective drugs and respiratory system drugs was relatively high, 13.
58%, 14.
61%, and 35.
64%, respectively, due to the small scale of products, the performance decline of China's biopharmaceuticals could not be saved.
In the third quarter of 2020, anti-tumor drug revenue was 1.
637 billion yuan, an increase of only 8.
42% year-on-year.
Although the revenue growth rate of orthopedic drugs, anti-infective drugs and respiratory system drugs was relatively high, 13.
58%, 14.
61%, and 35.
64%, respectively, due to the small scale of products, the performance decline of China's biopharmaceuticals could not be saved.
However, as the “king of the first imitation” in China, China Biopharmaceuticals, while carrying out the strategic transformation of combining innovation and imitation, is also constantly strengthening its traditional advantages, attacking the first imitation drugs and difficult imitation drugs, and only making the first three imitations.
It will help reduce the risk of centralized procurement of its generic drugs in the future.
It will help reduce the risk of centralized procurement of its generic drugs in the future.
When traditional areas of advantage are impacted, investment and license introduction are becoming its new growth point and innovative transformation means.
Although it is not too early to start on the road of innovation and transformation, with its strong extensional cooperation capabilities, China Biopharmaceuticals has a trend of overtaking in corners.
In terms of licensing, China Biopharmaceuticals signed agreements with companies such as Abpro, Ambrx, and Octapharma AG to introduce products such as double antibodies, innovative drugs for liver disease, and human albumin.
，biotech。、；1.
5D；5……
5D；5……
，，2015，、，。
201910，，4.
522.
5，。，27，21.
45%。
522.
5，。，27，21.
45%。
，。20156，23。，145，17.
78，，。
78，，。
20208，CEO，。，。
02 PE“”
，“”。
1994（），。1998，，A，“”。201210，H，A+H。
，、、。
In 2009, Fosun Pharma and a team of overseas scientists formed a joint venture, Fosun Pharma, and began to get involved in the research and development of small molecule chemical drugs.
In 2010, Fuhong Henlius was established and began to deploy in the fields of tumors, autoimmune diseases, and ophthalmological diseases.
In the same year, Fosun Pharma and U.
S.
China Mutual Co.
, Ltd.
jointly established a joint venture company U.
S.
China Mutual Medical Co.
, Ltd.
in Hong Kong to enter the field of medical devices.
In the same year, Fosun Pharma and U.
S.
China Mutual Co.
, Ltd.
jointly established a joint venture company U.
S.
China Mutual Medical Co.
, Ltd.
in Hong Kong to enter the field of medical devices.
In 2013, Fosun Pharma established Fu Rui Medical and acquired Alma, a medical beauty equipment manufacturer.
While expanding the medical device product system, Fosun Pharma also achieved the first international industrial holding acquisition.
While expanding the medical device product system, Fosun Pharma also achieved the first international industrial holding acquisition.
In 2015, Fosun Pharma, Hopu Investment, Everbright and WuXi AppTec jointly acquired Ambrx, an innovative biopharmaceutical company in the United States.
Ambrx focuses on the discovery and development of innovative and cutting-edge protein drugs, and has developed pipelines including ADCs, bispecific and multispecific antibody drug complexes, and long-acting therapeutic proteins.
The acquisition of Ambrx is an expansion of Fosun Pharma in the field of innovative oncology drugs.
Ambrx focuses on the discovery and development of innovative and cutting-edge protein drugs, and has developed pipelines including ADCs, bispecific and multispecific antibody drug complexes, and long-acting therapeutic proteins.
The acquisition of Ambrx is an expansion of Fosun Pharma in the field of innovative oncology drugs.
In 2016, Fosun Pharma acquired Gland Pharma, an Indian pharmaceutical company, which provided strong support for it in the field of generic drugs.
In 2017, Fosun Pharma acquired the Swedish respiratory equipment company Breas and began to deploy the respiratory medicine business.
In the same year, Fosun Pharma acquired Tridem Pharma, the third largest pharmaceutical distribution company in the French-speaking area of West Africa, to expand the sales scale of its independently developed artesunate series products in the African market.
In the same year, Fosun Pharma and Kite Pharma (a subsidiary of Gilead) co-founded Fosun Kate and entered the field of T cell immunotherapy.
In the same year, Fosun Pharma acquired Tridem Pharma, the third largest pharmaceutical distribution company in the French-speaking area of West Africa, to expand the sales scale of its independently developed artesunate series products in the African market.
In the same year, Fosun Pharma and Kite Pharma (a subsidiary of Gilead) co-founded Fosun Kate and entered the field of T cell immunotherapy.
In 2018, Fosun Pharma invested in Butterfly Network to deploy super-generating imagers for smartphones to improve the accessibility of its medical service business.
In 2019, Fu Rui Medical acquired a 60% stake in Medicak Israel Ltd, an Israeli medical beauty distribution company.
In addition to acquiring the company, Fosun Pharma has successively acquired Zhejiang Dean Diagnostics, Yueyang Guangji Hospital , Anhui Jimin Cancer Hospital, United Family Hospital, Zhongwu Hospital, Nanyang Cancer Hospital and other hospitals.
To many cities and regions.
To many cities and regions.
In the past ten years, continuous investment and mergers and acquisitions have allowed Fosun Pharma to have more than 50 branches and holding companies, and this data has a tendency to expand.
Acquisition-style expansion has made investment income gradually become an important source of profit for Fosun Pharma, and Fosun Pharma is therefore known as the "PE" of the pharmaceutical industry.
Acquisition-style expansion has made investment income gradually become an important source of profit for Fosun Pharma, and Fosun Pharma is therefore known as the "PE" of the pharmaceutical industry.
The layout of Fosun Pharma's entire industrial chain is not only reflected in the acquisition of the company, but also in the introduction and research and development of blockbuster drugs.
In March 2018, Fosun Pharma introduced a new generation of TPO-RA drug avatropopag (trade name: Su Kexin), which is used for the treatment of thrombocytopenia and was approved for marketing in 2020.
In 2019, Fuhong Henlius' rituximab (trade name: Hanlikang) was approved for marketing, becoming the first domestic biosimilar drug.
Fosun Kate’s Car-T treatment is also about to be commercialized in China.
In 2020, BioNtech's new crown vaccine will be the first to "hit the line" and become the world's first new crown vaccine on the market.
Fosun Pharma's earlier introduction of BioNtech's new crown vaccine also fully demonstrated its unique vision for selection.
In 2019, Fuhong Henlius' rituximab (trade name: Hanlikang) was approved for marketing, becoming the first domestic biosimilar drug.
Fosun Kate’s Car-T treatment is also about to be commercialized in China.
In 2020, BioNtech's new crown vaccine will be the first to "hit the line" and become the world's first new crown vaccine on the market.
Fosun Pharma's earlier introduction of BioNtech's new crown vaccine also fully demonstrated its unique vision for selection.
According to data from the report of the third quarter of 2020 by Fosun Pharma, from January to September 2020, its research and development expenses reached 1.
87 billion yuan, which was an increase of 45.
5% compared with the 1.
29 billion yuan investment in research and development from January to September 2019.
Mainly to invest in research and development of biological drugs, small molecule innovative drugs and imported innovative drugs, and increase investment in innovation incubation platforms.
The opening of the independent research and development model gives Fosun Pharma another opportunity to show its vision.
87 billion yuan, which was an increase of 45.
5% compared with the 1.
29 billion yuan investment in research and development from January to September 2019.
Mainly to invest in research and development of biological drugs, small molecule innovative drugs and imported innovative drugs, and increase investment in innovation incubation platforms.
The opening of the independent research and development model gives Fosun Pharma another opportunity to show its vision.
As a company with a history of 88 years, Yuanda Pharmaceuticals has a stronger "buy, buy and buy" force than the previous two companies.
Broad Pharmaceutical was established in 1939 and joined China Broad Group in 2002.
In 2008, it was listed on the Hong Kong stock market.
In the same year, the acquisition of Wuhan Yuanda Hongyuan Co.
, Ltd.
was completed, and it was deployed in the field of amino acid production.
In 2008, it was listed on the Hong Kong stock market.
In the same year, the acquisition of Wuhan Yuanda Hongyuan Co.
, Ltd.
was completed, and it was deployed in the field of amino acid production.
In the following years, Yuanda Pharmaceutical started its acquisition and expansion road.
Acquired BROAD Tiantianming Pharmaceuticals and BROAD Fuchs Pharmaceuticals one after another to deploy in the field of ophthalmology and chemical medicine; acquired Wuhan Kono Biotechnology and entered the field of biological pesticides; acquired Hubei Shubang Pharmaceutical to enhance its competitiveness in the field of pharmaceutical production; Established a joint venture company with Huangshi Feiyun Pharmaceutical to expand its layout in traditional Chinese medicine and drug production; acquired Huajin Pharmaceutical to increase its competitiveness in the field of generic drugs; completed the acquisition of Jiuhe Pharmaceutical to increase its exposure to APIs Control; acquired Cardionovum of Germany and entered the field of cardiovascular interventional therapy; the acquisition of Xi'an Beilin Pharmaceutical Co.
, Ltd.
continued to supplement its layout in the field of ophthalmic drugs; joint venture into the Canadian Conavi company to enter the field of cardiovascular diagnostics; acquisition of Xudong Haipu Pharmaceutical It strengthened its control over the production of injection drugs; and CDH Investment spent nearly RMB 10 billion to acquire 100% of the shares of Sirtex, a listed Australian pharmaceutical company, and Broad Pharmaceuticals began to enter the field of interventional oncology.
, Ltd.
continued to supplement its layout in the field of ophthalmic drugs; joint venture into the Canadian Conavi company to enter the field of cardiovascular diagnostics; acquisition of Xudong Haipu Pharmaceutical It strengthened its control over the production of injection drugs; and CDH Investment spent nearly RMB 10 billion to acquire 100% of the shares of Sirtex, a listed Australian pharmaceutical company, and Broad Pharmaceuticals began to enter the field of interventional oncology.
Similarly, in addition to acquisitions, Yuanda Pharmaceutical also does not forget to invest in companies and "buy drugs.
"
"
In 2019, Broad Pharmaceutical obtained the Chinese market rights and interests of Indian pharmaceutical giant Glenmark's global new compound nasal spray product Ryaltris through investment.
In the same year, Broad Pharmaceutical signed an exclusive authorization and cooperative development agreement with Griffith University of Australia, and obtained the global development and commercialization rights of the world's first products for the treatment of parainfluenza and related technologies.
In addition, it has acquired the global development and commercialization rights of sepsis drugs from the Australian National Research University (ANU), and cooperates with them to develop sepsis drugs.
In the same year, Broad Pharmaceutical signed an exclusive authorization and cooperative development agreement with Griffith University of Australia, and obtained the global development and commercialization rights of the world's first products for the treatment of parainfluenza and related technologies.
In addition, it has acquired the global development and commercialization rights of sepsis drugs from the Australian National Research University (ANU), and cooperates with them to develop sepsis drugs.
In 2020, Grand Pharmaceuticals invested in Quanfu Biotechnology and Chongqing Antixin Biotechnology Co.
, Ltd.
, and included the world's first product BRM421 for the treatment of dry eye and the world's first new drug technology for the treatment of sepsis APAD.
In addition, it has also obtained the exclusive production and commercialization rights of CBT001, a global innovative ophthalmic product developed by Boyun Pharmaceutical, in the Chinese market.
, Ltd.
, and included the world's first product BRM421 for the treatment of dry eye and the world's first new drug technology for the treatment of sepsis APAD.
In addition, it has also obtained the exclusive production and commercialization rights of CBT001, a global innovative ophthalmic product developed by Boyun Pharmaceutical, in the Chinese market.
Of course, the acquisition and investment of foreign companies in Yuanda Pharmaceutical has not stopped.
In 2020, Broad Pharmaceutical acquired the controlling stake of OncoSec, a US-listed Nasdaq company, and acquired TAVO, the world's first tumor immunotherapy product.
By investing in Belgium's eTheRNA, Yuanda Pharmaceutical has introduced mRNA vaccine platform technology to expand its layout in the field of tumor immunotherapy and infectious disease treatment.
In 2020, Broad Pharmaceutical acquired the controlling stake of OncoSec, a US-listed Nasdaq company, and acquired TAVO, the world's first tumor immunotherapy product.
By investing in Belgium's eTheRNA, Yuanda Pharmaceutical has introduced mRNA vaccine platform technology to expand its layout in the field of tumor immunotherapy and infectious disease treatment.
However, with seemingly similar investment, mergers and acquisitions and licensing introduction models, China Biopharmaceuticals, Fosun Pharma, and Yuanda Pharmaceuticals have handed in different answers.
According to Flush data, as of press time, the market value of China Biopharmaceuticals was 160.
32 billion Hong Kong dollars (approximately 133.
35 billion yuan), Fosun Pharmaceuticals had a market value of 117.
38 billion yuan, and Broad Pharmaceuticals had a market value of 21.
9 billion Hong Kong dollars (approximately 18.
22 billion yuan).
According to Flush data, as of press time, the market value of China Biopharmaceuticals was 160.
32 billion Hong Kong dollars (approximately 133.
35 billion yuan), Fosun Pharmaceuticals had a market value of 117.
38 billion yuan, and Broad Pharmaceuticals had a market value of 21.
9 billion Hong Kong dollars (approximately 18.
22 billion yuan).
On the whole, behind the gap in market value are more comprehensive tests of market judgment, R&D and product selection capabilities.
Medical News, February 26.
In the current pharmaceutical industry, the self-research and innovative development model represented by Hengrui and the M&A expansion model represented by Fosun are the two most typical expansion models of pharmaceutical companies.
In the current pharmaceutical industry, the self-research and innovative development model represented by Hengrui and the M&A expansion model represented by Fosun are the two most typical expansion models of pharmaceutical companies.
Driven by capital, local veteran pharmaceutical giants, who have built their pharmaceutical kingdom through investment and mergers and achieved rapid expansion, are showing their magical powers in order to realize the two-wheel drive of endogenous and extension.
At the current stage, the R&D model of independent R&D + external M&A + license introduction is becoming a way for pharmaceutical giants to endogenously extend and integrate vertically.
At the current stage, the R&D model of independent R&D + external M&A + license introduction is becoming a way for pharmaceutical giants to endogenously extend and integrate vertically.
Under the capital layout, the pharmaceutical giants quickly enriched the product pipelines in core areas and completed the pipeline layout of innovative products in the core areas, providing new momentum for medium and long-term growth.
01 founder Wang to return A copy of the
01 founder Wang to return A copy of the "Shocked! Zhongsheng is going back to the Science and Technology Innovation Board.
"
"
On the evening of February 3, China Biopharmaceuticals announced that it plans to be listed on the Science and Technology Innovation Board.
According to the announcement, all the stocks to be issued by China Biopharmaceutical on the Sci-tech Innovation Board are new shares, and the funds raised are intended to be used for the development of main business, mergers and acquisitions and integration in the industry, and general working capital.
According to the announcement, all the stocks to be issued by China Biopharmaceutical on the Sci-tech Innovation Board are new shares, and the funds raised are intended to be used for the development of main business, mergers and acquisitions and integration in the industry, and general working capital.
China Biopharmaceuticals' pace of returning to A is approaching.
On the evening of February 23, the official website of the Beijing Securities Regulatory Bureau disclosed the basic information of CICC and CITIC Securities on the IPO guidance of China Biopharmaceutical Co.
, Ltd.
on the Science and Technology Innovation Board.
China Biopharmaceutical Co.
, Ltd.
has signed a counseling agreement with CICC and CITIC Securities on February 8, 2021.
, Ltd.
on the Science and Technology Innovation Board.
China Biopharmaceutical Co.
, Ltd.
has signed a counseling agreement with CICC and CITIC Securities on February 8, 2021.
Sino Biopharmaceuticals was listed on the main board of the Hong Kong Stock Exchange in September 2000.
So far, its market value has exceeded 160 billion Hong Kong dollars.
It is reported that China Biopharma's business covers the entire industry chain of various pharmaceutical research and development platforms, intelligent production and strong sales systems.
Its products include a variety of biological drugs and chemical drugs, and are in an advantageous position in many potential therapeutic fields such as liver disease, tumor, orthopedics, anti-infection and respiratory diseases.
So far, its market value has exceeded 160 billion Hong Kong dollars.
It is reported that China Biopharma's business covers the entire industry chain of various pharmaceutical research and development platforms, intelligent production and strong sales systems.
Its products include a variety of biological drugs and chemical drugs, and are in an advantageous position in many potential therapeutic fields such as liver disease, tumor, orthopedics, anti-infection and respiratory diseases.
It is true that the pharmaceutical empire of a giant with a market value of hundreds of billions was not built in a day.
，。1997，、、、、、。
，pharmnet.
com.
cn/news/yyzb/" target="_blank">。
pharmnet. com.
cn/news/yyzb/" target="_blank">。
com.
cn/news/yyzb/" target="_blank">pharmnet.
com.
cn/news/yyzb/" target="_blank">
2020，54.
78，19.
36%，14.
75%。，13.
13%，7.
5%。
78，19.
36%，14.
75%。，13.
13%，7.
5%。
。，，，2020。2020，8.
03，52.
03%。
03，52.
03%。
，。2020，16.
37，8.
42%。、，13.
58%、14.
61%、35.
64%，，。
37，8.
42%。、，13.
58%、14.
61%、35.
64%，，。
“”，，、，。
，。
，，。
In terms of licensing, China Biopharmaceuticals signed agreements with companies such as Abpro, Ambrx, and Octapharma AG to introduce products such as double antibodies, innovative drugs for liver disease, and human albumin.
Not only is it licensed to introduce, China Biopharmaceuticals has also frequently invested in local emerging biotech companies in recent years.
Appeared in the prospectus of Yasheng Pharmaceutical and Rongchang Biological as a cornerstone investor ; led the US$150 million round D financing of Kangfang Biological; invested more than US$500 million in Kexing Zhongwei to promote the new crown vaccine project.
.
.
Medicine Medicine MedicineAppeared in the prospectus of Yasheng Pharmaceutical and Rongchang Biological as a cornerstone investor ; led the US$150 million round D financing of Kangfang Biological; invested more than US$500 million in Kexing Zhongwei to promote the new crown vaccine project.
.
.
China Biopharmaceuticals is controlled by Xie Bing, executive vice president of Thailand's CP Group and his family.
Xie Bing single-handedly founded China Biopharmaceuticals and has been in charge for many years.
Since 2015, Xie Bing’s daughter Xie Qirun and son Xie Chengrun have gradually stepped onto the front desk, and China Biopharmaceuticals have gradually Enter a new era.
Xie Bing single-handedly founded China Biopharmaceuticals and has been in charge for many years.
Since 2015, Xie Bing’s daughter Xie Qirun and son Xie Chengrun have gradually stepped onto the front desk, and China Biopharmaceuticals have gradually Enter a new era.
In October 2019, China Biopharmaceuticals announced that the executive director and major shareholders Xie Bing and Zheng Xiangling had transferred 450 million and 2.
25 billion company shares, respectively, to their son Xie Chengrun as gifts.
After the completion of the transfer, Xie Chengrun held a total of 2.
7 billion shares of the company, and its shareholding ratio reached 21.
45%.
25 billion company shares, respectively, to their son Xie Chengrun as gifts.
After the completion of the transfer, Xie Chengrun held a total of 2.
7 billion shares of the company, and its shareholding ratio reached 21.
45%.
In addition to Xie Chengrun, Xie Bing's daughter Xie Qirun is also worth mentioning.
In June 2015, Xie Bing ceded the chairman of the board to his 23-year-old daughter Xie Qirun.
And half a year after taking over China Biopharmaceutical Company, Xie Qirun handed over an answer sheet with an annual revenue of 14.
5 billion yuan and a profit of 1.
778 billion yuan, successfully breaking all previous records of China Biopharmaceutical Company and setting a new high profit.
In June 2015, Xie Bing ceded the chairman of the board to his 23-year-old daughter Xie Qirun.
And half a year after taking over China Biopharmaceutical Company, Xie Qirun handed over an answer sheet with an annual revenue of 14.
5 billion yuan and a profit of 1.
778 billion yuan, successfully breaking all previous records of China Biopharmaceutical Company and setting a new high profit.
In August 2020, Xie Bing resigned as CEO of China Biopharmaceuticals, and instead hired Li Yi, a former senior executive of JP Morgan Chase, with an annual salary of tens of millions.
Now it seems that Li Yi’s participation may bring more changes to this established pharmaceutical company from the capital market.
Now it seems that Li Yi’s participation may bring more changes to this established pharmaceutical company from the capital market.
02 PE "Family History" in the pharmaceutical industry
02 PE "Family History" in the pharmaceutical industry Fosun Pharma and Broad Pharmaceutical, both of which are capital giants, are representatives of "buy, buy, buy".
Shanghai Fosun Industrial Co.
, Ltd.
(now Fosun Pharma), established in 1994, is the first and most important step for Fosun Group to enter the pharmaceutical industry.
In 1998, Fosun Pharma was successfully listed on the Shanghai Stock Exchange and listed on the A-share market, becoming the "first share" of a private company in Shanghai.
In October 2012, Fosun Pharma successfully completed the issuance and listing of H shares in Hong Kong, forming a capital market layout of A+H shares.
, Ltd.
(now Fosun Pharma), established in 1994, is the first and most important step for Fosun Group to enter the pharmaceutical industry.
In 1998, Fosun Pharma was successfully listed on the Shanghai Stock Exchange and listed on the A-share market, becoming the "first share" of a private company in Shanghai.
In October 2012, Fosun Pharma successfully completed the issuance and listing of H shares in Hong Kong, forming a capital market layout of A+H shares.
Relying on investment and mergers and acquisitions, Fosun Pharma quickly entered the fields of pharmaceuticals, medical devices , and medical services.
Medical equipment medical equipment medical equipment In 2009, Fosun Pharma and a team of overseas scientists formed a joint venture, Fosun Pharma, and began to get involved in the research and development of small molecule chemical drugs.
In 2010, Fuhong Henlius was established and began to deploy in the fields of tumors, autoimmune diseases, and ophthalmological diseases.
In the same year, Fosun Pharma and U.
S.
China Mutual Co.
, Ltd.
jointly established a joint venture company U.
S.
China Mutual Medical Co.
, Ltd.
in Hong Kong to enter the field of medical devices.
In the same year, Fosun Pharma and U.
S.
China Mutual Co.
, Ltd.
jointly established a joint venture company U.
S.
China Mutual Medical Co.
, Ltd.
in Hong Kong to enter the field of medical devices.
In 2013, Fosun Pharma established Fu Rui Medical and acquired Alma, a medical beauty equipment manufacturer.
While expanding the medical device product system, Fosun Pharma also achieved the first international industrial holding acquisition.
While expanding the medical device product system, Fosun Pharma also achieved the first international industrial holding acquisition.
In 2015, Fosun Pharma, Hopu Investment, Everbright and WuXi AppTec jointly acquired Ambrx, an innovative biopharmaceutical company in the United States.
Ambrx focuses on the discovery and development of innovative and cutting-edge protein drugs, and has developed pipelines including ADCs, bispecific and multispecific antibody drug complexes, and long-acting therapeutic proteins.
The acquisition of Ambrx is an expansion of Fosun Pharma in the field of innovative oncology drugs.
Ambrx focuses on the discovery and development of innovative and cutting-edge protein drugs, and has developed pipelines including ADCs, bispecific and multispecific antibody drug complexes, and long-acting therapeutic proteins.
The acquisition of Ambrx is an expansion of Fosun Pharma in the field of innovative oncology drugs.
In 2016, Fosun Pharma acquired Gland Pharma, an Indian pharmaceutical company, which provided strong support for it in the field of generic drugs.
In 2017, Fosun Pharma acquired the Swedish respiratory equipment company Breas and began to deploy the respiratory medicine business.
In the same year, Fosun Pharma acquired Tridem Pharma, the third largest pharmaceutical distribution company in the French-speaking area of West Africa, to expand the sales scale of its independently developed artesunate series products in the African market.
In the same year, Fosun Pharma and Kite Pharma (a subsidiary of Gilead) co-founded Fosun Kate and entered the field of T cell immunotherapy.
In the same year, Fosun Pharma acquired Tridem Pharma, the third largest pharmaceutical distribution company in the French-speaking area of West Africa, to expand the sales scale of its independently developed artesunate series products in the African market.
In the same year, Fosun Pharma and Kite Pharma (a subsidiary of Gilead) co-founded Fosun Kate and entered the field of T cell immunotherapy.
In 2018, Fosun Pharma invested in Butterfly Network to deploy super-generating imagers for smartphones to improve the accessibility of its medical service business.
In 2019, Fu Rui Medical acquired a 60% stake in Medicak Israel Ltd, an Israeli medical beauty distribution company.
In addition to acquiring the company, Fosun Pharma has successively acquired Zhejiang Dean Diagnostics, Yueyang Guangji Hospital , Anhui Jimin Cancer Hospital, United Family Hospital, Zhongwu Hospital, Nanyang Cancer Hospital and other hospitals.
To many cities and regions.
Hospital hospital hospitalTo many cities and regions.
In the past ten years, continuous investment and mergers and acquisitions have allowed Fosun Pharma to have more than 50 branches and holding companies, and this data has a tendency to expand.
Acquisition-style expansion has made investment income gradually become an important source of profit for Fosun Pharma, and Fosun Pharma is therefore known as the "PE" of the pharmaceutical industry.
Acquisition-style expansion has made investment income gradually become an important source of profit for Fosun Pharma, and Fosun Pharma is therefore known as the "PE" of the pharmaceutical industry.
The layout of Fosun Pharma's entire industrial chain is not only reflected in the acquisition of the company, but also in the introduction and research and development of blockbuster drugs.
In March 2018, Fosun Pharma introduced a new generation of TPO-RA drug avatropopag (trade name: Su Kexin), which is used for the treatment of thrombocytopenia and was approved for marketing in 2020.
In 2019, Fuhong Henlius' rituximab (trade name: Hanlikang) was approved for marketing, becoming the first domestic biosimilar drug.
Fosun Kate’s Car-T treatment is also about to be commercialized in China.
In 2020, BioNtech's new crown vaccine will be the first to "hit the line" and become the world's first new crown vaccine on the market.
Fosun Pharma's earlier introduction of BioNtech's new crown vaccine also fully demonstrated its unique vision for selection.
In 2019, Fuhong Henlius' rituximab (trade name: Hanlikang) was approved for marketing, becoming the first domestic biosimilar drug.
Fosun Kate’s Car-T treatment is also about to be commercialized in China.
In 2020, BioNtech's new crown vaccine will be the first to "hit the line" and become the world's first new crown vaccine on the market.
Fosun Pharma's earlier introduction of BioNtech's new crown vaccine also fully demonstrated its unique vision for selection.
According to data from the report of the third quarter of 2020 by Fosun Pharma, from January to September 2020, its research and development expenses reached 1.
87 billion yuan, which was an increase of 45.
5% compared with the 1.
29 billion yuan investment in research and development from January to September 2019.
Mainly to invest in research and development of biological drugs, small molecule innovative drugs and imported innovative drugs, and increase investment in innovation incubation platforms.
The opening of the independent research and development model gives Fosun Pharma another opportunity to show its vision.
87 billion yuan, which was an increase of 45.
5% compared with the 1.
29 billion yuan investment in research and development from January to September 2019.
Mainly to invest in research and development of biological drugs, small molecule innovative drugs and imported innovative drugs, and increase investment in innovation incubation platforms.
The opening of the independent research and development model gives Fosun Pharma another opportunity to show its vision.
As a company with a history of 88 years, Yuanda Pharmaceuticals has a stronger "buy, buy and buy" force than the previous two companies.
Broad Pharmaceutical was established in 1939 and joined China Broad Group in 2002.
In 2008, it was listed on the Hong Kong stock market.
In the same year, the acquisition of Wuhan Yuanda Hongyuan Co.
, Ltd.
was completed, and it was deployed in the field of amino acid production.
In 2008, it was listed on the Hong Kong stock market.
In the same year, the acquisition of Wuhan Yuanda Hongyuan Co.
, Ltd.
was completed, and it was deployed in the field of amino acid production.
In the following years, Yuanda Pharmaceutical started its acquisition and expansion road.
Acquired BROAD Tiantianming Pharmaceuticals and BROAD Fuchs Pharmaceuticals one after another to deploy in the field of ophthalmology and chemical medicine; acquired Wuhan Kono Biotechnology and entered the field of biological pesticides; acquired Hubei Shubang Pharmaceutical to enhance its competitiveness in the field of pharmaceutical production; Established a joint venture company with Huangshi Feiyun Pharmaceutical to expand its layout in traditional Chinese medicine and drug production; acquired Huajin Pharmaceutical to increase its competitiveness in the field of generic drugs; completed the acquisition of Jiuhe Pharmaceutical to increase its exposure to APIs Control; acquired Cardionovum of Germany and entered the field of cardiovascular interventional therapy; the acquisition of Xi'an Beilin Pharmaceutical Co.
, Ltd.
continued to supplement its layout in the field of ophthalmic drugs; joint venture into the Canadian Conavi company to enter the field of cardiovascular diagnostics; acquisition of Xudong Haipu Pharmaceutical It strengthened its control over the production of injection drugs; and CDH Investment spent nearly RMB 10 billion to acquire 100% of the shares of Sirtex, a listed Australian pharmaceutical company, and Broad Pharmaceuticals began to enter the field of interventional oncology.
, Ltd.
continued to supplement its layout in the field of ophthalmic drugs; joint venture into the Canadian Conavi company to enter the field of cardiovascular diagnostics; acquisition of Xudong Haipu Pharmaceutical It strengthened its control over the production of injection drugs; and CDH Investment spent nearly RMB 10 billion to acquire 100% of the shares of Sirtex, a listed Australian pharmaceutical company, and Broad Pharmaceuticals began to enter the field of interventional oncology.
Similarly, in addition to acquisitions, Yuanda Pharmaceutical also does not forget to invest in companies and "buy drugs.
"
"
In 2019, Broad Pharmaceutical obtained the Chinese market rights and interests of Indian pharmaceutical giant Glenmark's global new compound nasal spray product Ryaltris through investment.
In the same year, Broad Pharmaceutical signed an exclusive authorization and cooperative development agreement with Griffith University of Australia, and obtained the global development and commercialization rights of the world's first products for the treatment of parainfluenza and related technologies.
In addition, it has acquired the global development and commercialization rights of sepsis drugs from the Australian National Research University (ANU), and cooperates with them to develop sepsis drugs.
In the same year, Broad Pharmaceutical signed an exclusive authorization and cooperative development agreement with Griffith University of Australia, and obtained the global development and commercialization rights of the world's first products for the treatment of parainfluenza and related technologies.
In addition, it has acquired the global development and commercialization rights of sepsis drugs from the Australian National Research University (ANU), and cooperates with them to develop sepsis drugs.
In 2020, Grand Pharmaceuticals invested in Quanfu Biotechnology and Chongqing Antixin Biotechnology Co.
, Ltd.
, and included the world's first product BRM421 for the treatment of dry eye and the world's first new drug technology for the treatment of sepsis APAD.
In addition, it has also obtained the exclusive production and commercialization rights of CBT001, a global innovative ophthalmic product developed by Boyun Pharmaceutical, in the Chinese market.
, Ltd.
, and included the world's first product BRM421 for the treatment of dry eye and the world's first new drug technology for the treatment of sepsis APAD.
In addition, it has also obtained the exclusive production and commercialization rights of CBT001, a global innovative ophthalmic product developed by Boyun Pharmaceutical, in the Chinese market.
Of course, the acquisition and investment of foreign companies in Yuanda Pharmaceutical has not stopped.
In 2020, Broad Pharmaceutical acquired the controlling stake of OncoSec, a US-listed Nasdaq company, and acquired TAVO, the world's first tumor immunotherapy product.
By investing in Belgium's eTheRNA, Yuanda Pharmaceutical has introduced mRNA vaccine platform technology to expand its layout in the field of tumor immunotherapy and infectious disease treatment.
In 2020, Broad Pharmaceutical acquired the controlling stake of OncoSec, a US-listed Nasdaq company, and acquired TAVO, the world's first tumor immunotherapy product.
By investing in Belgium's eTheRNA, Yuanda Pharmaceutical has introduced mRNA vaccine platform technology to expand its layout in the field of tumor immunotherapy and infectious disease treatment.
，、，、。，，1603.
2（1333.
5），1173.
8，219（182.
2）。
2（1333.
5），1173.
8，219（182.
2）。
，，、。
